Personalis (NASDAQ:PSNL) Releases Quarterly Earnings Results

Personalis (NASDAQ:PSNL) released its quarterly earnings results on Thursday. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.09, Zacks reports. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Personalis updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Personalis Stock Performance

Shares of PSNL stock opened at $4.24 on Friday. The firm has a market cap of $299.55 million, a P/E ratio of -2.52 and a beta of 1.73. Personalis has a fifty-two week low of $1.13 and a fifty-two week high of $7.20. The business’s 50 day moving average price is $5.43 and its 200-day moving average price is $5.04.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several recent research reports. Needham & Company LLC reduced their price objective on Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Friday. Lake Street Capital raised their price target on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Personalis in a research report on Friday.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.